Brief: FDA Grants Lantern Pharma Orphan Drug Designation For Drug Candidate Lp-284 In High-Grade B-Cell Lymphomas (Hgbl)
30/11/2023 13:09
Lantern Pharma Inc LTRN.O :
* FDA GRANTS LANTERN PHARMA ORPHAN DRUG DESIGNATION FOR DRUG
CANDIDATE LP-284 IN HIGH-GRADE B-CELL LYMPHOMAS (HGBL)
Source text for Eikon: ID:nBw5xwpjha
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments